Hui-Chih Develops Growth Strategy Centered on Reproductive and Cancer Precision Medicine

Details

Hui-Chih (6615) revealed its future growth strategy at a corporate briefing. The company is enhancing services in the reproductive medicine sector by upgrading PGT-A technology and expanding high-level testing through cooperation with Baylor Genetics of the US. Furthermore, in cancer precision medicine, capitalizing on the expansion of NGS testing and targeted drug coverage by the National Health Insurance (NHI), they are deepening companion diagnostics (CDx) in high-incidence cancers like gynecological and breast cancer. Notably, digital transformation has advanced significantly: the company completed clinical data exchange validation and NGS data loading mechanism drills using FHIR (Fast Healthcare Interoperability Resources). This establishes a complete digital process from structuring test results to EHR integration and insurance claims filing, aiming to improve service efficiency and client retention. Through these diversified efforts, the company aims to capitalize on the accelerating precision medicine market for medium-to-long term growth.